CD274 and melanoma: Immune-checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, have revolutionized cancer treatment, demonstrating durable responses in high immunogenicity tumors such as melanoma and non-small-cell lung cancer, and their clinical application is expanding year by year [2].